Warn­ing let­ter is­sued to New Jer­sey gener­ics man­u­fac­tur­er over qual­i­ty con­trol is­sues

A gener­ics man­u­fac­tur­er has re­ceived a warn­ing let­ter from the FDA over sev­er­al is­sues sur­round­ing su­per­vi­sion and qual­i­ty con­trol.

Bi-Coastal Phar­ma In­ter­na­tion­al’s drug man­u­fac­tur­ing fa­cil­i­ty …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER